Linaclotide in the treatment of patients with irritable bowel syndrome and constipation - Analysis of an opportunity;Linaclotida en el tratamiento de pacientes con síndrome del intestino irritable con estreñimiento: Análisis de una oportunidad

Revista Espanola de Enfermedades Digestivas

Volumn 105, Issue 6, 2013, Pages 345-354

  Carballo, Fernando ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Constipation; Irritable bowel syndrome; Visceral pain

Indexed keywords

LINACLOTIDE; PLACEBO; PEPTIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTICLE; BLOATING; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IRRITABLE COLON; NONHUMAN; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SYNDROME DELINEATION; VALIDITY; VISCERAL PAIN; CLINICAL TRIAL (TOPIC); IRRITABLE BOWEL SYNDROME;

CLINICAL TRIALS AS TOPIC; CONSTIPATION; HUMANS; IRRITABLE BOWEL SYNDROME; PEPTIDES;

EID: 84887512496     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082013000600006     Document Type: Article

References (44)

1. CHMP summary of positive opinion for Constella. EMA/ CHMP/604998/2012. 2012. [Consultado 26/02/2013]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_ of_opinion_-_Initial_authorisation/human/002490/WC500132840.pdf
2. Mearin F, Lacy BE. Diagnostic criteria in IBS: Useful or not? Neurogastroenterol Motil 2012;24:791-801.
3. Fortea J, Prior M. Irritable bowel syndrome with constipation: A European-focused systematic literature review of disease burden. J Med Econ 2013;16:329-41.
4. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
5. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-21 e4.
6. Caballero-Plasencia AM, Sofos-Kontoyannis S, Valenzuela-Barranco M, Martin-Ruiz JL, Casado-Caballero FJ, Lopez-Manas JG. Irritable bowel syndrome in patients with dyspepsia: A community-based study in southern Europe. Eur J Gastroenterol Hepatol 1999;11:517-22.
7. Mearin F, Badia X, Balboa A, Baro E, Caldwell E, Cucala M, et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: Comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol 2001;36:1155-61.
8. Rey E, Mearin F. Prevalencia de trastornos funcionales intestinales en la poblacion espanola y su asociacion con sintomas digestivos altos. Rev Esp Enferm Dig 2012;104 (Supl. 1):89-90.
9. Mearin F. Without doubt, functional digestive disorders constitute one of the main reasons for consultation in both gastroenterology and primary health care. Foreword. J Clin Gastroenterol 2011;45 (Supl.):S81.
10. Fedorak RN, Vanner SJ, Paterson WG, Bridges RJ. Canadian Digestive Health Foundation Public Impact Series 3: Irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol 2012;26:252-6.
11. Mitra D, Davis KL, Baran RW. All-cause health care charges among managed care patients with constipation and comorbid irritable bowel syndrome. Postgrad Med 2011;123:122-32.
12. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Am 2011;40:11-9.
13. Rey E, Garcia-Alonso MO, Moreno-Ortega M, Alvarez-Sanchez A, Diaz-Rubio M. Determinants of quality of life in irritable bowel syndrome. J Clin Gastroenterol 2008;42:1003-9.
14. Pique JM, Lanas A. Sindrome del intestino irritable: una enfermedad con una elevada carga socioeconomica y sanitaria. Aten Primaria 2006;38:69-71.
15. Dibonaventura MD, Prior M, Prieto P, Fortea J. Burden of constipation-predominant irritable bowel syndrome (IBS-C) in France, Italy, and the United Kingdom. Clin Exp Gastroenterol 2012;5:203-12.
16. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-61.
17. Clave P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, et al. Randomised clinical trial: Otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2011;34:432-42.
18. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: Systematic review and meta-analysis. Gut 2009;58:367-78.
19. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984;29:239-47.
20. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl 1987;130:81-4.
21. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996;31:463-8.
22. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: The efficacy of treatments for irritable bowel syndrome-a European perspective. Aliment Pharmacol Ther 2006;24:183-205.
23. Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008;6:545-55.
24. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-96.
25. Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, et al. Clinical trial: Lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-41.
26. Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012;35:587-99.
27. Potter LR. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther 2011;130:71-82.
28. Corsetti M, Tack J. Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation. United European Gastroenterology Journal 2013;1:7-20.
29. Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010;649:328-35.
30. Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010;22:312-e84.
31. Brierley SM. Guanylate cyclase-C receptor activation: Unexpected biology. Curr Opin Pharmacol 2012;12:632-40.
32. Vazquez Roque M, Camilleri M. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev Gastroenterol Hepatol 2011;5:301-10.
33. Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther 2013;344:196-206.
34. Johnston JM, Kurtz CB, Drossman DA, Lembo AJ, Jeglinski BI, Mac-Dougall JE, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009;104:125-32.
35. Lembo AJ, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010;138:886-95 e1.
36. Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8.
37. Johnston JM, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010;139:1877-86 e2.
38. Johnston JM, Schneier HA. Clarification of trial end points presented in a recent review of linaclotide. Expert Rev Gastroenterol Hepatol 2012;6:13-4.
39. Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527-36.
40. Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714-24.
41. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, et al. Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702-12.
42. European Medicines Agency. Points to Consider on the Evaluation of Medicinal Products for the Treatment of Irritable Bowel Syndrome. 2003. [Consultado 26/02/2013]. Disponible en: http://www. ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/ 2009/09/WC500003187.pdf.
43. Guidance for industry: irritable bowel syndrome-clinical evaluation of drugs for treatment. Food and Drug Administration. 2012. [Consultado 26/02/2013]. Disponible en: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM205269.pdf.
44. Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, et al. Randomised clinical trials: Linaclotide phase 3 studies in IBS-C-A prespecified further analysis based on European Medicines Agencyspecified endpoints. Aliment Pharmacol Ther 2013;37:49-61.